MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctarc.2023.100743

Медицинская библиотека · Cancer treatment and research communications · 2023

Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.

Desai Aakash, Rakshit Sagar, Bansal Radhika, Ashara Yash, Potter Ashley, Manochakian Rami, Lou Yanyan, Zhao Yujie, Ernani Vinicius, Savvides Panos, Schwecke Anna, Moffett Nicole, Hocum Craig, Leventakos Konstantinos, Adjei Alex, Marks Randolph, Molina Julian, Mansfield Aaron S, Chen Zong-Ming, Dimou Anastasios

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

We evaluated the risk factors and outcomes for patients who experienced hepatotoxicity after use of sotorasib in KRAS G12C mutated NSCLC.

METHODS

Retrospective review of medical records of patients with KRAS G12C mutated NSCLC who received sotorasib between May 28th, 2021, and December 31st, 2021 across all Mayo Clinic sites, with follow up until December 31st, 2022.

RESULTS

Thirty-one patients received sotorasib as standard of care treatment. Grade 3 or higher hepatoxicity was seen in 32% (10/31) patients presenting at a median of 51 days (range, 27-123) of sotorasib initiation. Baseline demographics were comparable between patients with and without ≥grade 3 hepatotoxicity, except for presence of CNS metastases and time from prior immune checkpoint inhibitor (ICI) treatment. Improvement in liver tests was observed in all patients after stopping sotorasib, and it was restarted at a lower dose in 8 patients. Despite dose reduction, hepatotoxicity requiring sotorasib discontinuation occurred in 2 patients. Twenty-eight of 31 patients had received prior ICI. Median time from prior ICI therapy was 69 days (range, 4-542). Rates of ≥grade 3 hepatoxicity were 75% (3/4), 64% (7/11) and 0% (0/13) for patients who received ICI within 30 days, 31-90 days and >90 days. None of the 3 patients without prior ICI exposure developed hepatoxicity. The median PFS and OS were 3.9 months and 9.9 months respectively.

CONCLUSION

One-third of patients developed grade 3 or higher sotorasib induced hepatotoxicity. Risk of hepatotoxicity was higher in patients who received sotorasib within 90 days of ICI treatment.

Для цитирования: Desai Aakash, Rakshit Sagar, Bansal Radhika, Ashara Yash, Potter Ashley, Manochakian Rami, Lou Yanyan, Zhao Yujie, Ernani Vinicius, Savvides Panos, Schwecke Anna, Moffett Nicole, Hocum Craig, Leventakos Konstantinos, Adjei Alex, Marks Randolph, Molina Julian, Mansfield Aaron S, Chen Zong-Ming, Dimou Anastasios. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.. Cancer treatment and research communications. 2023. DOI: 10.1016/j.ctarc.2023.100743.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.